交易 Kymera Therapeutics, Inc. - KYMR CFD
新增到我的最愛- 摘要
- 曆史數據
- 活動
- 盈虧控制
- 資産負債表
- 現金流
交易條件
價差 | 0.10 | ||||||||
多頭倉位隔夜費用
多頭隔夜費用
前往平台 | -0.026179% | ||||||||
空頭倉位隔夜費用
空頭隔夜費用
前往平台 | 0.003957% | ||||||||
隔夜費時間 | 21:00 (UTC) | ||||||||
最小成交量 | 1 | ||||||||
貨幣 | USD | ||||||||
保證金 | 5% | ||||||||
股票交易 | United States of America | ||||||||
交易委員會 | 0% |
*Information provided by Capital.com
Kymera Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 拋售 | 自訂 | 變化 (%) | 打開 | 最高 | 最小 |
---|---|---|---|---|---|---|
Apr 18, 2024 | 35.10 | 1.96 | 5.91% | 33.14 | 35.50 | 33.14 |
Apr 17, 2024 | 33.69 | -0.22 | -0.65% | 33.91 | 34.11 | 33.10 |
Apr 16, 2024 | 33.87 | 0.14 | 0.42% | 33.73 | 34.67 | 33.29 |
Apr 15, 2024 | 34.33 | -1.18 | -3.32% | 35.51 | 35.66 | 34.16 |
Apr 12, 2024 | 35.54 | -0.39 | -1.09% | 35.93 | 36.78 | 34.69 |
Apr 11, 2024 | 37.16 | 1.63 | 4.59% | 35.53 | 37.22 | 35.28 |
Apr 10, 2024 | 35.25 | -0.28 | -0.79% | 35.53 | 36.32 | 35.01 |
Apr 9, 2024 | 37.56 | 1.27 | 3.50% | 36.29 | 37.58 | 35.91 |
Apr 8, 2024 | 36.30 | -0.08 | -0.22% | 36.38 | 36.86 | 35.56 |
Apr 5, 2024 | 36.36 | 0.65 | 1.82% | 35.71 | 37.12 | 35.16 |
Apr 4, 2024 | 36.15 | -1.16 | -3.11% | 37.31 | 37.91 | 35.96 |
Apr 3, 2024 | 36.99 | -0.92 | -2.43% | 37.91 | 37.91 | 36.49 |
Apr 2, 2024 | 37.56 | -0.48 | -1.26% | 38.04 | 38.50 | 36.71 |
Apr 1, 2024 | 39.32 | -0.99 | -2.46% | 40.31 | 40.31 | 38.14 |
Mar 28, 2024 | 40.13 | 0.00 | 0.00% | 40.13 | 40.53 | 39.24 |
Mar 27, 2024 | 40.09 | 1.04 | 2.66% | 39.05 | 40.17 | 38.89 |
Mar 26, 2024 | 39.40 | -0.38 | -0.96% | 39.78 | 40.20 | 38.94 |
Mar 25, 2024 | 39.42 | -0.44 | -1.10% | 39.86 | 41.20 | 39.20 |
Mar 22, 2024 | 40.62 | 1.45 | 3.70% | 39.17 | 41.20 | 39.17 |
Mar 21, 2024 | 40.73 | 0.23 | 0.57% | 40.50 | 41.76 | 40.50 |
Kymera Therapeutics, Inc. Events
時間 (UTC) | 國家 | 事件 |
---|---|---|
Thursday, May 2, 2024 | ||
時間 (UTC) 12:30 | 國家 US
| 事件 Q1 2024 Kymera Therapeutics Inc Earnings Release Q1 2024 Kymera Therapeutics Inc Earnings ReleaseForecast(預報) -返回 - |
Friday, June 14, 2024 | ||
時間 (UTC) 13:00 | 國家 US
| 事件 Kymera Therapeutics Inc Annual Shareholders Meeting Kymera Therapeutics Inc Annual Shareholders MeetingForecast(預報) -返回 - |
Thursday, August 1, 2024 | ||
時間 (UTC) 12:30 | 國家 US
| 事件 Q2 2024 Kymera Therapeutics Inc Earnings Release Q2 2024 Kymera Therapeutics Inc Earnings ReleaseForecast(預報) -返回 - |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 46.826 | 72.832 | 34.034 | 2.934 | 0 |
收入 | 46.826 | 72.832 | 34.034 | 2.934 | 0 |
總營業費用 | 208.082 | 173.362 | 80.338 | 45.139 | 21.451 |
銷售/一般/行政費用,總計 | 43.834 | 36.345 | 18.233 | 7.981 | 3.772 |
研究與開發 | 164.248 | 137.017 | 62.105 | 37.158 | 17.679 |
營業收入 | -161.256 | -100.53 | -46.304 | -42.205 | -21.451 |
利息收入(費用),非經營淨值 | 6.448 | 0.313 | 0.711 | 0.959 | -0.016 |
稅前淨收入 | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
稅後淨收入 | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
未計算非常項目前的淨收益 | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
淨收入 | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
普通股股東可獲收益 (不含非經常性項目) | -154.808 | -100.217 | -54.643 | -41.246 | -21.467 |
普通股股東可獲收益 (含非經常性項目) | -154.808 | -100.217 | -54.643 | -41.246 | -21.467 |
攤薄淨收入 | -154.808 | -100.217 | -54.643 | -41.246 | -21.467 |
攤薄後加權平均股 | 53.9332 | 47.989 | 44.4822 | 43.1386 | 43.1386 |
扣除特別項目的每股攤薄盈利 | -2.87036 | -2.08833 | -1.22842 | -0.95613 | -0.49763 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
每股正常攤薄盈利 | -2.87036 | -2.08833 | -1.22842 | -0.95613 | -0.49763 |
Total Adjustments to Net Income | 0 | -9.05 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 16.513 | 9.466 | 16.139 | 9.551 | 11.514 |
收入 | 16.513 | 9.466 | 16.139 | 9.551 | 11.514 |
總營業費用 | 59.896 | 54.792 | 54.769 | 54.433 | 52.324 |
銷售/一般/行政費用,總計 | 14.129 | 12.565 | 11.636 | 10.556 | 11.031 |
研究與開發 | 45.767 | 42.227 | 43.133 | 43.877 | 41.293 |
營業收入 | -43.383 | -45.326 | -38.63 | -44.882 | -40.81 |
利息收入(費用),非經營淨值 | 4.584 | 4.398 | 3.765 | 1.88 | 0.553 |
稅前淨收入 | -38.799 | -40.928 | -34.865 | -43.002 | -40.257 |
稅後淨收入 | -38.799 | -40.928 | -34.865 | -43.002 | -40.257 |
未計算非常項目前的淨收益 | -38.799 | -40.928 | -34.865 | -43.002 | -40.257 |
淨收入 | -38.799 | -40.928 | -34.865 | -43.002 | -40.257 |
Total Adjustments to Net Income | |||||
普通股股東可獲收益 (不含非經常性項目) | -38.799 | -40.928 | -34.865 | -43.002 | -40.257 |
普通股股東可獲收益 (含非經常性項目) | -38.799 | -40.928 | -34.865 | -43.002 | -40.257 |
攤薄淨收入 | -38.799 | -40.928 | -34.865 | -43.002 | -40.257 |
攤薄後加權平均股 | 58.327 | 58.187 | 57.9326 | 54.5355 | 51.7724 |
扣除特別項目的每股攤薄盈利 | -0.6652 | -0.70339 | -0.60182 | -0.78851 | -0.77758 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.6652 | -0.70339 | -0.60182 | -0.78851 | -0.77758 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 419.416 | 451.273 | 302.339 | 92.845 | 41.79 |
現金和短期投資 | 407.166 | 442.418 | 296.202 | 91.957 | 41.26 |
現金等價物 | 68.395 | 47.976 | 31.004 | 76.015 | 41.26 |
短期投資 | 338.771 | 394.442 | 265.198 | 15.942 | 0 |
應收賬款總額,淨額 | 2.537 | 0.135 | 1.433 | 0 | 0.148 |
預付的費用 | 9.713 | 8.72 | 4.704 | 0.888 | 0.382 |
總資産 | 603.134 | 605.905 | 487.175 | 116.702 | 44.231 |
物業/廠房/設備,總計 - 淨額 | 22.243 | 21.307 | 20.686 | 22.083 | 2.242 |
物業/廠房/設備,總計 - 總額 | 29.136 | 25.223 | 22.833 | 23.132 | 2.466 |
累計折舊,總計 | -6.893 | -3.916 | -2.147 | -1.049 | -0.224 |
其他長期資産,總計 | 9.147 | 8.138 | 1.619 | 1.774 | 0.199 |
流動負債總額 | 71.343 | 92.542 | 110.617 | 34.57 | 4.687 |
應付賬款 | 4.335 | 4.005 | 4.368 | 3.276 | 2.056 |
預提費用 | 29.63 | 25.08 | 12.896 | 7.175 | 2.225 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
長期債務的當前部分/資本租賃 | 1.408 | 1.138 | 0.689 | 0.681 | 0.302 |
其他流動負債,總計 | 35.97 | 62.319 | 92.664 | 23.438 | 0.104 |
負債總額 | 112.983 | 146.267 | 203.287 | 82.028 | 5.238 |
長期債務總額 | 1.246 | 1.14 | 0.604 | 1.165 | 0.393 |
資本租賃義務 | 1.246 | 1.14 | 0.604 | 1.165 | 0.393 |
其他負債,總計 | 40.394 | 52.585 | 92.066 | 46.293 | 0.158 |
股權 | 490.151 | 459.638 | 283.888 | 34.674 | 38.993 |
Redeemable Preferred Stock | 109.08 | 73.429 | |||
普通股 | 0.006 | 0.005 | 0.004 | 0 | 0 |
額外實收資本 | 878.884 | 689.275 | 412.777 | 2.044 | 0.774 |
留存收益(累計赤字) | -383.79 | -228.982 | -128.765 | -76.456 | -35.21 |
其他權益,總計 | -4.949 | -0.66 | -0.128 | 0.006 | 0 |
總負債和股東權益 | 603.134 | 605.905 | 487.175 | 116.702 | 44.231 |
已發行普通股總數 | 55.0394 | 51.5362 | 44.4822 | 43.1386 | 43.1386 |
應收賬款 - 貿易,淨額 | 2.537 | 0.135 | 0.856 | ||
長期投資 | 152.328 | 125.187 | 162.531 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 375.694 | 385.402 | 411.55 | 419.416 | 494.022 |
現金和短期投資 | 357.825 | 367.574 | 396.877 | 407.166 | 481.908 |
現金等價物 | 81.051 | 52.386 | 50.152 | 68.395 | 155.658 |
短期投資 | 276.774 | 315.188 | 346.725 | 338.771 | 326.25 |
應收賬款總額,淨額 | 3.778 | 4.122 | 3.32 | 2.537 | 2.882 |
應收賬款 - 貿易,淨額 | 3.778 | 4.122 | 3.32 | 2.537 | 2.882 |
預付的費用 | 14.091 | 13.706 | 11.353 | 9.713 | 9.232 |
總資産 | 552.378 | 581.945 | 613.905 | 603.134 | 638.472 |
物業/廠房/設備,總計 - 淨額 | 91.1 | 83.181 | 74.036 | 22.243 | 21.617 |
物業/廠房/設備,總計 - 總額 | 100.649 | 91.872 | 81.827 | 29.136 | 27.692 |
累計折舊,總計 | -9.549 | -8.691 | -7.791 | -6.893 | -6.075 |
長期投資 | 76.988 | 104.759 | 119.017 | 152.328 | 113.701 |
其他長期資産,總計 | 8.596 | 8.603 | 9.302 | 9.147 | 9.132 |
流動負債總額 | 63.166 | 54.602 | 61.933 | 71.343 | 91.124 |
應付賬款 | 4.978 | 3.745 | 6.483 | 4.335 | 6.327 |
預提費用 | 25.655 | 22.939 | 19.53 | 29.63 | 27.015 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
長期債務的當前部分/資本租賃 | 1.01 | 1.231 | 1.339 | 1.408 | 1.103 |
其他流動負債,總計 | 31.523 | 26.687 | 34.581 | 35.97 | 56.679 |
負債總額 | 156.843 | 146.517 | 151.9 | 112.983 | 125.587 |
長期債務總額 | 0.643 | 0.762 | 0.989 | 1.246 | 0.69 |
資本租賃義務 | 0.643 | 0.762 | 0.989 | 1.246 | 0.69 |
其他負債,總計 | 93.034 | 91.153 | 88.978 | 40.394 | 33.773 |
股權 | 395.535 | 435.428 | 462.005 | 490.151 | 512.885 |
普通股 | 0.006 | 0.006 | 0.006 | 0.006 | 0.006 |
額外實收資本 | 914.363 | 902.574 | 889.755 | 878.884 | 867.717 |
留存收益(累計赤字) | -516.384 | -463.517 | -424.718 | -383.79 | -348.925 |
其他權益,總計 | -2.45 | -3.635 | -3.038 | -4.949 | -5.913 |
總負債和股東權益 | 552.378 | 581.945 | 613.905 | 603.134 | 638.472 |
已發行普通股總數 | 55.4502 | 55.3903 | 55.2762 | 55.0394 | 54.7514 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
淨收入/起跑線 | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
經營活動産生的現金 | -153.085 | -128.946 | 88.13 | 17.905 | -17.863 |
經營活動産生的現金 | 2.977 | 2.397 | 1.763 | 0.825 | 0.205 |
非現金物品 | 36.369 | 30.797 | 7.093 | 1.639 | 1.091 |
已付現金利息 | 0.179 | 0.158 | 0.115 | 0.046 | 0.015 |
營運資金的變化 | -37.623 | -61.923 | 124.867 | 56.687 | 2.308 |
投資活動産生的現金 | 20.519 | -99.835 | -422.588 | -16.486 | -1.356 |
資本支出 | -2.836 | -1.597 | -9.096 | -0.532 | -1.356 |
其他投資現金流量項目,總計 | 23.355 | -98.238 | -413.492 | -15.954 | 0 |
融資活動産生的現金 | 152.999 | 250.28 | 289.262 | 34.911 | 52.932 |
股票的發行(報廢),淨額 | 154.129 | 249.18 | 276.289 | 35.282 | 53.227 |
債務的發行(退還),淨額 | -1.13 | -0.849 | -0.554 | -0.371 | -0.295 |
現金淨變化 | 20.433 | 21.499 | -45.196 | 36.33 | 33.713 |
融資現金流項目 | 0 | 1.949 | 13.527 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -40.928 | -154.808 | -119.943 | -76.941 | -36.684 |
Cash From Operating Activities | -43.968 | -153.085 | -113.549 | -79.28 | -40.295 |
Cash From Operating Activities | 0.879 | 2.977 | 2.159 | 1.392 | 0.687 |
Non-Cash Items | 8.059 | 36.369 | 28.365 | 19.347 | 9.048 |
Cash Interest Paid | 0.052 | 0.179 | 0.124 | 0.086 | 0.046 |
Changes in Working Capital | -11.978 | -37.623 | -24.13 | -23.078 | -13.346 |
Cash From Investing Activities | 24.584 | 20.519 | 70.185 | 107.666 | 25.863 |
Capital Expenditures | -4.009 | -2.836 | -2.463 | -1.217 | -0.482 |
Other Investing Cash Flow Items, Total | 28.593 | 23.355 | 72.648 | 108.883 | 26.345 |
Cash From Financing Activities | 1.159 | 152.999 | 151.046 | 0.549 | 0.185 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 1.486 | 154.129 | 151.871 | 1.082 | 0.449 |
Issuance (Retirement) of Debt, Net | -0.327 | -1.13 | -0.825 | -0.533 | -0.264 |
Net Change in Cash | -18.225 | 20.433 | 107.682 | 28.935 | -14.247 |
差價合約交易計算器
計算您的假設損益
交易佣金
0
- 1:1
槓桿
1:1
- 20
- 100
- 500
- 1000
- 10000
交易
交易規模(槓桿 x 投資):
打開
拋售
已賣出 做多
Industry: | Biotechnology & Medical Research (NEC) |
200 Arsenal Yards Blvd., Suite 230
WATERTOWN
MASSACHUSETTS 02472
US
盈虧控制
- Annual
- Quarterly
人們也觀看
還在尋找值得信賴的經紀商?
加入全球 610,000 多名交易者,選擇與 Capital.com 交易